AlphaQuest’s Neuropace NPCE Stock Holding History

AlphaQuest’s Portfolio NPCE Stock Details NPCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-8,952	Closed	-$138K	–	1354
2025 Q4	$138K	Sell	8,952 -8,135	-48%	-$109K	0.01%	1610
2025 Q3	$176K	Buy	17,087 +9,707	+132%	+$91.5K	0.01%	1469
2025 Q2	$82.2K	Buy	+7,380	New	+$92.3K	0.01%	1490

Other funds holding NPCE

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

AlphaQuest's NPCE Position: Q1 2026 in Review

AlphaQuest sold out of Neuropace (NPCE) in Q1 2026, closing a stake of 8,952 shares — an estimated $138K sold.

AlphaQuest first reported a position in NPCE in Q2 2025 and held it in 3 quarters. The position peaked at $176K in Q3 2025. 113 funds tracked by Wall St. Rank hold NPCE as of Q1 2026.

AlphaQuest reported no remaining Neuropace position as of Q1 2026 after selling out during the quarter.
AlphaQuest sold 8,952 Neuropace shares in Q1 2026, an estimated $138K.
AlphaQuest first reported a position in Neuropace in Q2 2025 and held it in 3 quarters.
AlphaQuest's Neuropace position peaked at $176K in Q3 2025.
113 funds tracked by Wall St. Rank held Neuropace as of Q1 2026.

Based on AlphaQuest's 13F filing for Q1 2026.